Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.
|
|
Integrated Regional Information Networks - September 16, 2003
Despite the pharmaceutical company's pledge, the Ugandan government has been unable to obtain key antiretrovirals at the reduced price.
The government has been told by GlaxoSmithKline (GSK) officials that it must first purchase the existing stock of the company's ARVs in Uganda "at the previous - and higher - prices, before being able to take advantage of [GlaxoSmithKline's] new ... pricing for developing world countries," said a statement by the AIDS Healthcare Foundation, an NGO running free AIDS treatment clinics in Uganda and South Africa.
"GSK is reneging on its commitment to lower AIDS drug prices in Africa, and many people with AIDS - who can't get these life-saving drugs because of GSK's pricing policies - will die," Michael Weinstein, president of AIDS Healthcare Foundation, warned in the statement.
Long under fire by AIDS advocates over its drug pricing and policies, GSK announced in April 2003 that it had cut the price of its leading Combivir treatment by 47 percent, to under US $1 a day in poor countries. Combivir, one of GSK's best-selling antiretroviral drugs, is a combination of two ARVs in one tablet.
The move was seen as a sign that the international pharmaceutical industry was bowing to pressure to improve access to treatment in Africa and other parts of the developing world, where HIV/AIDS has hit hardest.
"We are asking GSK to cut through the bureaucracy and make these drugs truly available and affordable in Africa and the developing world," Weinstein added.
A partnership between the ministry of health and the AIDS Healthcare Foundation is to kick-start an initiative that will offer ARVs to as many as 10,000 more Ugandans living with HIV/AIDS.
The announcement of the government's commitment to increasing treatment access came at the conclusion of a recent conference on scaling up treatment in the developing world, hosted by the AIDS Healthcare Foundation.
Uganda has an estimated 1.5 million people living with HIV/AIDS, of which 105,000 will need treatment in the next three to four years, according to figures from the Kampala-based Health Rights Action Group (HAG).
According to government figures released in February this year, up to 10,000 HIV-positive Ugandans are currently on treatment. Widely regarded as having successfully lowered the rates of HIV/AIDS infections, the country is now the leading user of ARV drugs on the continent.
030916
IR030925
Copyright © 2003 - Integrated Regional Information Networks (IRIN). Reproduction of this article (other than one copy for personal reference) must be cleared through the Integrated Regional Information Network. .
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980 – 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .